Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89401 | 0.96 | TSHR (0.71) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL89411 | 0.91 | TSHR (0.67) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL8264865 | 0.86 | REN (0.57) | TSHRHTTPOLBTP53THRB | |
| SCHEMBL10181988 | 0.86 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL1764373 | 0.86 | TSHR (0.62) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL1764374 | 0.85 | TSHR (0.61) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL10181902 | 0.85 | TSHR (0.64) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL13618628 | 0.84 | TSHR (0.64) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL4059758 | 0.84 | TSHR (0.64) | TSHRHTTPOLBTP53PLK1 | |
| SCHEMBL1047741 | 0.84 | REN (0.57) | TSHRHTTPOLBTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | TSHR 1095/4885HTT 943/4885POLB 589/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | TSHR 2757/4885HTT 1273/4885POLB 663/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | TSHR 3249/4885HTT 1746/4885POLB 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.